HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avon Q2 forecast

This article was originally published in The Rose Sheet

Executive Summary

Direct-seller reaffirms expectation that second quarter worldwide sales will rise approximately 4%, despite continued depressed results in Argentina, and that operating profits will increase by mid single-digits. In the U.S., sales predicted to advance 6%-7% in Q2 and operating profit to grow in low teens. For 2002, Avon predicting its third consecutive year of double-digit earnings growth. Firm is scheduled to report second quarter results July 19...

You may also be interested in...



Hikma And Civica Ship Eight Essential Injectables

Hikma and Civica Rx have announced the launch of a first wave of eight essential injectable medicines, including heparin, as part of a deal struck between the two firms earlier this year.

AstraZeneca's Calquence Steps Up in First-Line CLL

A PFS benefit and favorable tolerability profile associated with AstraZeneca’s BTK inhibitor acalabrutinib used first-line in CLL, when given alone or combined with obinutuzumab, may serve it well against entrenched competitors and BTK inhibitors in clinical development.

Amneal Takes Control Of AvKARE In US

Amneal has acquired a majority stake in manufacturer and wholesaler AvKARE, giving the firm access to the “large, complex and growing federal healthcare market.”

UsernamePublicRestriction

Register

RS010348

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel